Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	107.46	64.38	57.42	51.35	55.31
Revenue Growth (YoY)	66.92%	12.12%	11.84%	-7.17%	-23.03%
Selling, General & Admin	73.65	69.17	70.1	67.07	99.3
Research & Development	37.41	37.64	40.62	63.39	193.66
Other Operating Expenses	-	4.51	2.74	12.84	20.14
Total Operating Expenses	111.07	111.33	113.46	143.3	313.1
Operating Income	-3.6	-46.95	-56.04	-91.96	-257.78
Interest Expense	-2.46	-2.55	-2.35	-6.37	-8.55
Other Non-Operating Income (Expense)	135.31	4.88	9.12	5.51	1.11
Total Non-Operating Income (Expense)	132.85	2.34	6.77	-0.86	-7.44
Pretax Income	129.25	-44.61	-49.27	-92.82	-265.22
Provision for Income Taxes	23.35	11.8	5.92	178.98	-0.15
Net Income	105.9	-56.42	-55.19	693.16	-199.43
Earnings From Discontinued Operations	-	-	-	964.96	65.65
Net Income to Common	105.9	-56.42	-55.19	693.16	-199.43
Shares Outstanding (Basic)	50	49	55	74	69
Shares Outstanding (Diluted)	52	49	55	74	69
Shares Change (YoY)	5.45%	-11.67%	-24.85%	5.95%	11.41%
EPS (Basic)	2.10	-1.15	-1.00	11.85	-2.87
EPS (Diluted)	2.06	-1.15	-1.00	11.85	-2.87
Shares Outstanding	51.07	49.47	48.09	65.23	74.44
Free Cash Flow	238.5	-11.87	-29.49	-187.56	-211.26
Free Cash Flow Per Share	4.63	-0.24	-0.53	-2.55	-3.04
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-3.35%	-72.92%	-97.58%	-179.09%	-466.06%
Profit Margin	98.54%	-87.63%	-96.11%	-529.35%	-479.24%
FCF Margin	221.93%	-18.43%	-51.35%	-365.29%	-381.96%
EBITDA	2.04	-40.83	-49.88	-84.25	-249.2
EBITDA Margin	1.90%	-63.41%	-86.87%	-164.09%	-450.54%
EBIT	-3.6	-46.95	-56.04	-91.96	-257.78
EBIT Margin	-3.35%	-72.92%	-97.58%	-179.09%	-466.06%
Effective Tax Rate	18.07%	-26.46%	-12.02%	-192.84%	0.06%

Updated Mar 19, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q